| 货号 | 规格 | 价格 | 上海 | 北京 | 武汉 | 南京 | 购买数量 |
|---|---|---|---|---|---|---|---|
S80078-5mg |
99.9% | ￥90.00 | 6 | - | - | - |
|
S80078-10mg |
99.9% | ￥140.00 | 6 | - | - | - |
|
S80078-25mg |
99.9% | ￥340.00 | 6 | - | - | - |
|
S80078-50mg |
99.9% | ￥660.00 | 4 | - | - | - |
|
S80078-100mg |
99.9% | ￥1130.00 | 5 | - | - | - |
|
S80078-200mg |
≥99% | ￥2200.00 | 货期：2-3天 | - | - | - |
|
FH535 is an inhibitor of Wnt/β-catenin and PPAR, with anti-tumor activities.
| 产品描述： | FH535 is an inhibitor of Wnt/β-catenin and PPAR, with anti-tumor activities. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | PPAR;β-catenin;Wnt/beta-catenin;PPAR | ||||||||||||||||||||
| 体内研究： | FH535 (25 mg/kg, i.p.) exhibits an anti-tumor effect on pancreatic cancer xenografts in mice. FH535 also represses angiogenesis in pancreatic cancer xenografts | ||||||||||||||||||||
| 参考文献： | 1. Handeli S, et al. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther. 2008 Mar;7(3):521-9. 2. Wu MY, et al. FH535 inhibited metastasis and growth of pancreatic cancer cells. Onco Targets Ther. 2015 Jul 6;8:1651-70.3. Liu L, et al. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Oncotarget. 2016 Jul 26;7(30):47145-47162. | ||||||||||||||||||||
| 溶解性： | DMSO : 33.33 mg/mL (92.28 mM; Need ultrasonic) | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京